Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.

Abstract: In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

Abstract: The present invention features a composition comprising zinc pyrithione and silver sulfiadizine, a formulation thereof and a method of treating microbial infection using the composition.

Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.

Abstract: A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.

Abstract: The present invention relates to a composition comprising a stable aqueous dispersion of polymer particles comprising structural units of a polymerizable amino acid and structural units of an acid monomer or a salt thereof. The composition of the present invention is useful in improving lipstick stain resistance in coatings compositions.

Abstract: The present invention is directed to a method for treating a hair disorder in a human or animal in need thereof, involving topically applying to the human or animal an effective amount of at least one 6-substituted 2-pyridinol N-oxide compound, a tautomer, or a cosmetically acceptable salt thereof wherein a hair count is increased by at least 0.5 hairs/cm2 and/or an increase the number of anagen hairs and maintain the number of telogen hairs when compared to a baseline and/or vehicle.

Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. Pharmaceutical compositions are formed by suspending or dissolving a mixed metal complex of a compound of Formula I, or a salt thereof, in a liquid medium, optionally with one or more physiologically acceptable excipients. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.

Abstract: A novel class of heterodinuclear Pt—Ru complexes are provided, and the methods for preparing the complexes are described. The inhibitory activities of the heterodinuclear Pt—Ru complexes against cancer/tumor cell growth, including cancer/tumor cells having a resistance to cisplatin, are further demonstrated.

Abstract: The present invention provides compositions and methods for treatment of abnormal conditions in a subject, wherein the abnormal condition affects the musculoskeletal joints of the subject.

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.

Abstract: The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.

Abstract: A method for producing amino acid chelate compounds, characterized in that metal oxides and/or metal carbonates and/or metal sulfates and/or metal chlorides and/or metal hydroxides in solid form are activated mechanically and then the activated metal oxides and/or metal carbonates and/or metal hydroxides and/or metal sulfates and/or metal chlorides are brought together with amino acids in solid form and converted to amino acid chelate compounds in a solid-state reaction.

Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Abstract: The invention provides a compound of formula I: or a salt or prodrug thereof, wherein Y, W, Z, Z1, Z2, Z3, Z4, and R1-R12 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.

Abstract: A synergistic antimicrobial composition containing zoxamide and zinc pyrithione is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition.

Abstract: Microparticles containing an ultraviolet light absorbing polymer and 3-iodo-2-propynyl butylcarbamate (“IPBC”) resist discoloration by sunlight and other ultraviolet light sources. Methods for preparing the microparticles produce polymer-shielded, formaldehyde-free IPBC formulations which resist discoloration and leaching, and are especially useful in water-based applications. The microparticles include a polymer or a poly(vinyl formal) homopolymer that absorbs light over a range of ultraviolet wavelengths associated with IPBC discoloration. The microparticles may be utilized in paints, stains, stuccoes, adhesives, and plastics, for example.

Abstract: A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, Alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (GP), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention.

Abstract: A composition having biocidal properties is disclosed. The composition includes a first biocide, optionally a second biocide, and a biocide enhancing agent. The first biocide may comprise an isothiazolin. The second biocide may comprise a pyrithione. The biocide enhancing agent may comprise an amine, an amine salt, an amine oxide, or mixtures thereof. The amine compound may have a carbon chain length of at least six carbon atoms, such as at least eight carbon atoms.

Abstract: The present invention provides a method of protecting wood or other celiulosic material from decay by copper-tolerant fungi, and wood preservative formulations for use in the same. The wood preservative formulations comprise a biocidal metal compound, a 1,2,4-triazole and a didecyl quaternary ammonium cation. Didecyldimethyl quaternary ammonium compounds are particularly preferred.

Abstract: Non-spherical liquid droplets comprising a liquid, an internal solid material defining the shape of the droplet, a benefit agent, and methods of making non-spherical liquid droplets.

Abstract: Shape-changing droplets, compositions comprising shape-changing droplets, methods of depositing benefit agents onto substrates using shape-changing droplets, and methods of making shape-changing droplets.

Abstract: The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.

Abstract: A scalp care composition comprising from 1% to 99% of a volatile carrier; from 0.05% to 10% of a polymeric rheology modifier and mixtures thereof; from 0.03% to 1% of particulate scalp benefit agent wherein the composition is shear thinning and has (1) a zero shear viscosity value measured at 0.01 Pa of greater than about 1,500 Pa s; (2) a moderate stress viscosity value measured at 1 Pa viscosity of greater than about 1,000 Pa s; and (3) a high shear rate viscosity value measured at 100 1/s of less than about 0.5 Pa s.

Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Abstract: A mold-resistant paper is provided. The paper is coated on at least one surface with an anti-microbial coating which includes polymerized siloxane and a fungicide. An antimicrobial paper coating and related methods are provided as well. A gypsum panel with improved resistance to mold and mildew is provided as well.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more inorganic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of fludioxonil, pencycuron, ametoctradin, chloroneb, chlorothalonil, oxine-copper, cyflufenamid, dichlofluanid, dicloran, diethofencarb, dinocap, dithianon, edifenphos, fenaminosulf, fentin, fluazinam, fluoroimide, flusulfamide, flutianil, fosetyl-Al, hydrargaphen, iprobenfos, metrafenon, milneb, penflufen, phosdiphen, phthalide, prothiocarb, pyrazophos, sedaxane, silthiofam, spiroxamine, tebufloquin, and tolyfluanid.

Abstract: The invention relates to complexes of germanium with amino acids and carboxylic acids of the general formula Ge[OH]a[AA]b[CA]c (I), where AA is an amino acid, CA is a carboxylic acid, a=0-3, b=1-3, c=0-3, and 1<b+c?4, wherein AA and AC in the complex can be identical or different, and to a method for preparing same. The method preparing an aqueous suspension of germanium dioxide, adding an amino acid and a carboxylic acid to the aqueous suspension of germanium oxide produced, heating the mixture produced with agitation at a temperature of 40-100° C. for 2-14 hours with subsequent filtering, removal of the water and production of a complex in solid form. The method makes it possible to prepare stable complexes with a controllable composition and a control fable ratio of germanium to amino acid and carboxylic acid which are stable in solid form and can be used in medicine.

Abstract: A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.

Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.

Abstract: Compositions comprising dihydroavenanthramide D and climbazole; and, cosmetics or pharmaceutical end products comprising the compositions, useful for treating skin and/or hair.

Abstract: A medical or therapeutic application of a composite material of ruthenium with a nitrosyl ligand. Application for a medical or therapeutic treatment of a composite material of ruthenium with a nitrosyl ligand irradiated in a spectral range capable of releasing the nitrosyl ligand, i.e., the ultraviolet or visible or near-infrared spectral range.

Abstract: Cosmetic cleaning agents include in a cosmetically acceptable carrier a) at least one anionic surfactant, b) at least one cationic guar polymer, c) at least one silicone emulsion, in which the silicone particles have an average diameter of a maximum of 600 nm, and d) at least one wax. The cosmetic cleaning agents are suitable in particular for use as a shampoo. After application they impart improved properties to the hair treated therewith, in particular improved wet and dry combability.

Abstract: Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

Abstract: A cleansing composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, wherein 80% of the plurality of perfume raw materials comprise a FDV of at least 0.69.

Abstract: The present invention relates to a shampoo composition and methods of using the same. The shampoo composition includes a silicone grafted tapioca starch, a detersive surfactant, a cationic conditioning polymer, and a carrier. The shampoo composition can provide both conditioning and volume benefits.

Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.

Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.

Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:

Abstract: The present invention relates to an antimicrobial bar soap that contains zinc pyrithione and a metal-phosphonate complex and is characterized by enhanced discoloration resistance, extended shelf life and/or increased anti-microbial efficacy.

Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Abstract: Personal care composition and methods are included with respect to a dried zinc pyrithione-polymer aggregate.

Abstract: One form of the present invention provides a resin composition and a molded product formed thereof, wherein a polymer composition which includes a thermoplastic base polymer or base polyblend (A), a thermoplastic base polymer or base polyblend (B) having no compatibility with the (A), and fluid (C) included as a nanoparticle suspension having compatibility with neither (A) nor (B) and containing nanoparticles uniformly dispersed at a temperature lower than or equal to the thermal decomposition temperature of (A) or (B), and in which interfaces between three layers made of (A), (B), and (C) form three-dimensional continuous parallel interfaces, and the nanoparticles of (C) having an average particle size from 1 ?m to 1 nm after removal of a dispersion medium of (C) by evaporation are locally unevenly dispersed in the pattern of a curve or a straight line connecting consecutive points at a fracture surface, and are macroscopically uniformly dispersed.

Abstract: There is provided an antifouling coating composition capable of forming an antifouling coating film which has stable coating film consumption degree on ships, underwater structures and the like and which exhibits excellent antifouling property over a long term. The antifouling coating composition includes a hydrolyzable copolymer (A) and an antifouling agent (B), wherein the hydrolyzable copolymer (A) is, e.g., a metal salt bond-containing copolymer having a component unit derived from a monomer (a21) represented by the general formula (II): CH2?C(R2)—COO-M-O—CO—C(R2)?CH2??(II) [In the formula (II), M is zinc or copper, and R2 is a hydrogen atom or a methyl group], and a component unit derived from other unsaturated monomer (a22) copolymerizable with the monomer (a21), and wherein the antifouling agent (B) includes at least medetomidine.

Abstract: An object of the present invention is to make it possible that a pyridine antibacterial/antifungal agent is dispersed stably in a liquid for appropriate impartation of the pyridine antibacterial/antifungal agent to fibers, and that when fibers are processed with the agent which is mixed with various other treating agents such as dyes and softeners, there is no negative influences on the process of the fibers for imparting antibacterial/antifungal properties. An antibacterial/antifungal properties-imparting agent contains a pyridine antibacterial/antifungal agent; a modified polysaccharide having reduced hydroxyl groups; and a wetting agent; but does not contain a surfactant. After applying the antibacterial/antifungal properties-imparting agent to fibers, the fibers undergo a heating process.

Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.